schizandrin a has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, W; Xian, H; Zhang, J | 1 |
| Ding, Z; Hu, X; Liu, K; Liu, Z; Zhang, B | 1 |
1 trial(s) available for schizandrin a and Lung Neoplasms
| Article | Year |
|---|---|
Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cyclooctanes; Epithelial-Mesenchymal Transition; Female; Humans; Lignans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Polycyclic Compounds; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
1 other study(ies) available for schizandrin a and Lung Neoplasms
| Article | Year |
|---|---|
Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclooctanes; Drug Synergism; Gefitinib; Humans; I-kappa B Kinase; Lignans; Lung Neoplasms; Molecular Dynamics Simulation; NF-kappa B; Polycyclic Compounds; Protein Conformation; Signal Transduction | 2019 |